ALK	anaplastic lymphoma kinase
ATC	anaplastic thyroid cancer
CEA	carcinoembryonic antigen
CRC	colorectal cancer
CTLA-4	cytotoxic T-lymphocyte-associated protein 4
DCs	dendritic cells
DCR	disease control rate
dMMR	mismatch repair-deficient
DOR	duration of response
EGFR	epidermal growth factor receptor
EML4	EMAP-like 4
FDA	United States Food and Drug Administration
FLT3L	FMS-like tyrosine kinase 3 ligand
GDF15	growth differentiation factor 15
HER2	human epidermal growth factor receptor 2
HRR	homologous recombination repair
IHC	immunohistochemistry
InDel	insertions and deletions
LIFl	leukemia inhibitory factor 1
MAPK	Mitogen-activated protein kinase
MCL1	myeloid cell leukemia-1
mDOR	median duration of the response
MDSC	myeloid-derived suppressor cells
MEK1 and MEK2	mitogen-activated protein kinase 1 and 2
MIP	molecular imprinting polymers
MSI-H	metastatic microsatellite instability-high
NGR1	HER3-targeting arm to block neuregulin 1
NGS	Next-generation sequencing
NK	natural killer cell
NPM1	nucleophosmin 1
NSCLC	non-small-cell lung cancer
NTRK	neurotrophic receptor tyrosine kinase
ORR	objective response rate
OS	overall survival
PD-1	programmed death receptor 1
PD-L1	programmed death ligand 1
PFS	progression-free survival
P-GP	P-Glycoprotein
RET	rearranged during transfection
ROS1	receptor tyrosine kinase ROS proto-oncogene 1
TAAs	tumor-associated antigens
TAMs	tumor-ssociated macrophages
TNBC	triple-negative breast cancer
TCGA	The Cancer Genome Atlas Program
TME	tumor microenvironment
TLR	Toll-like receptor
TMB-H	high metastatic tumor mutational burden